MicroPhage gets FDA clearance for MRSA/MSSA bacteria test

05/8/2011 | Modern Healthcare (subscription required)

Colorado-based MicroPhage has received FDA clearance for its KeyPath MRSA/MSSA Blood Culture Test, which can rapidly distinguish between methicillin resistant and methicillin susceptible Staphylococcus aureus bacteria. The test "not only saves time in diagnosing potentially life-threatening infections but also allows health care professionals to optimize treatment and start appropriate contact precautions to prevent the spread of the organism," said Alberto Gutierrez, the director of the in vitro diagnostics unit at the FDA's device center.

View Full Article in:

Modern Healthcare (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX